Cargando…
Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign
INTRODUCTION: Information on post-infection and vaccine-induced SARS-CoV-2 seroprevalence is important for public health policies. A 3rd wave of National Serological Survey (ISN3COVID-19) was conducted to measure SARS-CoV-2 seroprevalence and characterize specific antibodies distribution in Portugue...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620794/ http://dx.doi.org/10.1093/eurpub/ckac131.411 |
_version_ | 1784821396540489728 |
---|---|
author | Kislaya, I Gonçalves, P Gaio, V Matos, R Barreto, M Melo, A Guiomar, R Rodrigues, A P ISNCOVID-19 group, PT |
author_facet | Kislaya, I Gonçalves, P Gaio, V Matos, R Barreto, M Melo, A Guiomar, R Rodrigues, A P ISNCOVID-19 group, PT |
author_sort | Kislaya, I |
collection | PubMed |
description | INTRODUCTION: Information on post-infection and vaccine-induced SARS-CoV-2 seroprevalence is important for public health policies. A 3rd wave of National Serological Survey (ISN3COVID-19) was conducted to measure SARS-CoV-2 seroprevalence and characterize specific antibodies distribution in Portuguese population in September - November 2021, following a mass vaccination campaign. METHODS: ISN3COVID-19 was a cross-sectional epidemiological study that collected serum samples and questionnaire data on a sample of Portuguese residents aged 1 year or older (n = 4545). SARS-CoV-2 IgG anti-nucleoprotein and anti-spike antibody levels were measured using Abbott Chemiluminescent Microparticle Immunoassays. Seroprevalence was estimated for the overall sample and stratified by age group, sex, region and self-reported chronic conditions. Medians and respective 95% confidence intervals (95%CI) were used to describe the distribution of SARS-CoV-2 antibodies in specific population subgroups. RESULTS: The overall seroprevalence of SARS-CoV-2 (post-infection or vaccine-induced) was 86.4% (95%CI: 85.2 to 87.6%), post-infection seroprevalence was 7.5% (95%CI: 6.6 to 8.5). Higher seroprevalence was observed among 50-59 years-old (96.5%), women (88.3%), and those with two or more self-reported chronic conditions (90.8%). Higher IgG (anti-Spike) levels were estimated for individuals vaccinated with the booster dose (median=12601.3 AU/ml; 95%CI: 4127.5 to 19089.1) and for those vaccinated with two doses of Spikevax® vaccine (median=7012.7 AU/ml, 95%CI: 5568.8 to 8456.6). CONCLUSIONS: The SARS-CoV-2 seroprevalence was high and consistent with vaccine coverage in Portugal. Seropositivity was associated with sex, age and previous chronic conditions. The anti-SARS-CoV-2 anti-spike IgG levels varied according to vaccine brand and number of doses. These results show that monitoring seroprevalence and SARS-CoV-2 antibody distribution is of paramount importance to guide public health policies. KEY MESSAGES: • Significant increase in SARS-CoV-2 seroprevalence following the mass vaccination campaign consistent with the high vaccine coverage achieved in Portugal. • Continuous monitoring of the population‐level IgG response after vaccination remains important to guide further public health measures. |
format | Online Article Text |
id | pubmed-9620794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-96207942022-11-04 Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign Kislaya, I Gonçalves, P Gaio, V Matos, R Barreto, M Melo, A Guiomar, R Rodrigues, A P ISNCOVID-19 group, PT Eur J Public Health Poster Displays INTRODUCTION: Information on post-infection and vaccine-induced SARS-CoV-2 seroprevalence is important for public health policies. A 3rd wave of National Serological Survey (ISN3COVID-19) was conducted to measure SARS-CoV-2 seroprevalence and characterize specific antibodies distribution in Portuguese population in September - November 2021, following a mass vaccination campaign. METHODS: ISN3COVID-19 was a cross-sectional epidemiological study that collected serum samples and questionnaire data on a sample of Portuguese residents aged 1 year or older (n = 4545). SARS-CoV-2 IgG anti-nucleoprotein and anti-spike antibody levels were measured using Abbott Chemiluminescent Microparticle Immunoassays. Seroprevalence was estimated for the overall sample and stratified by age group, sex, region and self-reported chronic conditions. Medians and respective 95% confidence intervals (95%CI) were used to describe the distribution of SARS-CoV-2 antibodies in specific population subgroups. RESULTS: The overall seroprevalence of SARS-CoV-2 (post-infection or vaccine-induced) was 86.4% (95%CI: 85.2 to 87.6%), post-infection seroprevalence was 7.5% (95%CI: 6.6 to 8.5). Higher seroprevalence was observed among 50-59 years-old (96.5%), women (88.3%), and those with two or more self-reported chronic conditions (90.8%). Higher IgG (anti-Spike) levels were estimated for individuals vaccinated with the booster dose (median=12601.3 AU/ml; 95%CI: 4127.5 to 19089.1) and for those vaccinated with two doses of Spikevax® vaccine (median=7012.7 AU/ml, 95%CI: 5568.8 to 8456.6). CONCLUSIONS: The SARS-CoV-2 seroprevalence was high and consistent with vaccine coverage in Portugal. Seropositivity was associated with sex, age and previous chronic conditions. The anti-SARS-CoV-2 anti-spike IgG levels varied according to vaccine brand and number of doses. These results show that monitoring seroprevalence and SARS-CoV-2 antibody distribution is of paramount importance to guide public health policies. KEY MESSAGES: • Significant increase in SARS-CoV-2 seroprevalence following the mass vaccination campaign consistent with the high vaccine coverage achieved in Portugal. • Continuous monitoring of the population‐level IgG response after vaccination remains important to guide further public health measures. Oxford University Press 2022-10-25 /pmc/articles/PMC9620794/ http://dx.doi.org/10.1093/eurpub/ckac131.411 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Displays Kislaya, I Gonçalves, P Gaio, V Matos, R Barreto, M Melo, A Guiomar, R Rodrigues, A P ISNCOVID-19 group, PT Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign |
title | Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign |
title_full | Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign |
title_fullStr | Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign |
title_full_unstemmed | Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign |
title_short | Seroprevalence and SARS-CoV-2 antibodies distribution in Portugal following mass vaccination campaign |
title_sort | seroprevalence and sars-cov-2 antibodies distribution in portugal following mass vaccination campaign |
topic | Poster Displays |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620794/ http://dx.doi.org/10.1093/eurpub/ckac131.411 |
work_keys_str_mv | AT kislayai seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT goncalvesp seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT gaiov seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT matosr seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT barretom seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT meloa seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT guiomarr seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT rodriguesap seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign AT isncovid19grouppt seroprevalenceandsarscov2antibodiesdistributioninportugalfollowingmassvaccinationcampaign |